Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Kazia Therapeutics ( (KZIA) ).
On December 10, 2025, Kazia Therapeutics announced promising new data from the San Antonio Breast Cancer Symposium regarding their drug paxalisib. The findings demonstrate paxalisib’s ability to reinvigorate anti-tumor immunity in advanced breast cancer populations, including TNBC and HER2+. The data, derived from advanced liquid biopsy profiling and immune phenotyping, suggest that paxalisib can disrupt aggressive circulating tumor cell clusters and enhance responsiveness to immunotherapy. This positions paxalisib as a potentially transformative agent in breast cancer treatment, offering new therapeutic opportunities beyond current HER2-targeted therapies and checkpoint inhibitors.
The most recent analyst rating on (KZIA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Kazia Therapeutics stock, see the KZIA Stock Forecast page.
Spark’s Take on KZIA Stock
According to Spark, TipRanks’ AI Analyst, KZIA is a Underperform.
Kazia Therapeutics has a low overall stock score due to significant financial instability marked by declining revenues, negative equity, and cash flow issues. Technical indicators suggest bearish momentum, and poor valuation metrics reflect the company’s unprofitability. The absence of dividends and positive earnings call or corporate events data further emphasize the company’s challenges.
To see Spark’s full report on KZIA stock, click here.
More about Kazia Therapeutics
Kazia Therapeutics Limited is an oncology-focused drug development company based in Sydney, Australia. The company is primarily engaged in the development of paxalisib, a brain-penetrant inhibitor targeting the PI3K/Akt/mTOR pathway, for treating various forms of cancer. Kazia’s lead program has been involved in multiple clinical trials, including those for glioblastoma, breast cancer, and brain metastases. The company also develops EVT801, a small molecule inhibitor of VEGFR3, which has shown potential in preclinical studies.
Average Trading Volume: 741,325
Technical Sentiment Signal: Hold
Current Market Cap: $26.26M
See more insights into KZIA stock on TipRanks’ Stock Analysis page.